Bannari Amman Sugars Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 8, 2025, 6:01 pm

Competitors of Bannari Amman Sugars Ltd

All Competitor Stocks of Bannari Amman Sugars Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:01 pm

Below is a detailed analysis of the quarterly data for Bannari Amman Sugars Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 419.00 Cr.. The value appears to be declining and may need further review. It has decreased from 494.00 Cr. (Mar 2025) to 419.00 Cr., marking a decrease of 75.00 Cr..
• For Expenses, as of Jun 2025, the value is 382.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 441.00 Cr. (Mar 2025) to 382.00 Cr., marking a decrease of 59.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 16.00 Cr..
• For OPM %, as of Jun 2025, the value is 9.00%. The value appears to be declining and may need further review. It has decreased from 11.00% (Mar 2025) to 9.00%, marking a decrease of 2.00%.
• For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 17.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 55.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 31.00 Cr..
• For Tax %, as of Jun 2025, the value is 37.00%. The value appears to be increasing, which may not be favorable. It has increased from 36.00% (Mar 2025) to 37.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 35.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 20.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 12.16. The value appears to be declining and may need further review. It has decreased from 28.04 (Mar 2025) to 12.16, marking a decrease of 15.88.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:27 pm

Growth

Last Updated: September 5, 2025, 12:35 am

Balance Sheet

Last Updated: December 4, 2025, 1:01 am

Below is a detailed analysis of the balance sheet data for Bannari Amman Sugars Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
• For Reserves, as of Sep 2025, the value is 1,809.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,766.00 Cr. (Mar 2025) to 1,809.00 Cr., marking an increase of 43.00 Cr..
• For Borrowings, as of Sep 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 150.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 131.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 340.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 297.00 Cr. (Mar 2025) to 340.00 Cr., marking an increase of 43.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 2,180.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,226.00 Cr. (Mar 2025) to 2,180.00 Cr., marking a decrease of 46.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 1,163.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,189.00 Cr. (Mar 2025) to 1,163.00 Cr., marking a decrease of 26.00 Cr..
• For CWIP, as of Sep 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 5.00 Cr..
• For Investments, as of Sep 2025, the value is 100.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 100.00 Cr., marking an increase of 96.00 Cr..
• For Other Assets, as of Sep 2025, the value is 902.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,022.00 Cr. (Mar 2025) to 902.00 Cr., marking a decrease of 120.00 Cr..
• For Total Assets, as of Sep 2025, the value is 2,180.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,226.00 Cr. (Mar 2025) to 2,180.00 Cr., marking a decrease of 46.00 Cr..

Notably, the Reserves (1,809.00 Cr.) exceed the Borrowings (19.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Bannari Amman Sugars Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 83.47. This value is within the healthy range. It has decreased from 121.46 (Mar 24) to 83.47, marking a decrease of 37.99.
• For Diluted EPS (Rs.), as of Mar 25, the value is 83.47. This value is within the healthy range. It has decreased from 121.46 (Mar 24) to 83.47, marking a decrease of 37.99.
• For Cash EPS (Rs.), as of Mar 25, the value is 130.13. This value is within the healthy range. It has decreased from 167.38 (Mar 24) to 130.13, marking a decrease of 37.25.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,418.60. It has increased from 1,346.44 (Mar 24) to 1,418.60, marking an increase of 72.16.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,418.60. It has increased from 1,346.44 (Mar 24) to 1,418.60, marking an increase of 72.16.
• For Dividend / Share (Rs.), as of Mar 25, the value is 12.50. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 12.50.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,429.84. It has decreased from 1,770.63 (Mar 24) to 1,429.84, marking a decrease of 340.79.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 188.64. This value is within the healthy range. It has decreased from 249.69 (Mar 24) to 188.64, marking a decrease of 61.05.
• For PBIT / Share (Rs.), as of Mar 25, the value is 141.98. This value is within the healthy range. It has decreased from 203.76 (Mar 24) to 141.98, marking a decrease of 61.78.
• For PBT / Share (Rs.), as of Mar 25, the value is 129.39. This value is within the healthy range. It has decreased from 178.52 (Mar 24) to 129.39, marking a decrease of 49.13.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 83.47. This value is within the healthy range. It has decreased from 121.46 (Mar 24) to 83.47, marking a decrease of 37.99.
• For PBDIT Margin (%), as of Mar 25, the value is 13.19. This value is within the healthy range. It has decreased from 14.10 (Mar 24) to 13.19, marking a decrease of 0.91.
• For PBIT Margin (%), as of Mar 25, the value is 9.92. This value is below the healthy minimum of 10. It has decreased from 11.50 (Mar 24) to 9.92, marking a decrease of 1.58.
• For PBT Margin (%), as of Mar 25, the value is 9.04. This value is below the healthy minimum of 10. It has decreased from 10.08 (Mar 24) to 9.04, marking a decrease of 1.04.
• For Net Profit Margin (%), as of Mar 25, the value is 5.83. This value is within the healthy range. It has decreased from 6.85 (Mar 24) to 5.83, marking a decrease of 1.02.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.88. This value is below the healthy minimum of 15. It has decreased from 9.02 (Mar 24) to 5.88, marking a decrease of 3.14.
• For Return on Capital Employeed (%), as of Mar 25, the value is 9.24. This value is below the healthy minimum of 10. It has decreased from 13.71 (Mar 24) to 9.24, marking a decrease of 4.47.
• For Return On Assets (%), as of Mar 25, the value is 4.70. This value is below the healthy minimum of 5. It has decreased from 6.25 (Mar 24) to 4.70, marking a decrease of 1.55.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.08. This value is within the healthy range. It has decreased from 0.28 (Mar 24) to 0.08, marking a decrease of 0.20.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 0.92 (Mar 24) to 0.76, marking a decrease of 0.16.
• For Current Ratio (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has increased from 2.09 (Mar 24) to 3.33, marking an increase of 1.24.
• For Quick Ratio (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.37, marking an increase of 0.05.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.89. This value is below the healthy minimum of 4. It has increased from 1.55 (Mar 24) to 1.89, marking an increase of 0.34.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 14.97. This value is below the healthy minimum of 20. It has increased from 10.29 (Mar 24) to 14.97, marking an increase of 4.68.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 9.60. This value is below the healthy minimum of 20. It has increased from 7.46 (Mar 24) to 9.60, marking an increase of 2.14.
• For Earning Retention Ratio (%), as of Mar 25, the value is 85.03. This value exceeds the healthy maximum of 70. It has decreased from 89.71 (Mar 24) to 85.03, marking a decrease of 4.68.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 90.40. This value exceeds the healthy maximum of 70. It has decreased from 92.54 (Mar 24) to 90.40, marking a decrease of 2.14.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 14.99. This value is within the healthy range. It has increased from 9.89 (Mar 24) to 14.99, marking an increase of 5.10.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.63. This value is within the healthy range. It has increased from 5.81 (Mar 24) to 7.63, marking an increase of 1.82.
• For Enterprise Value (Cr.), as of Mar 25, the value is 4,862.64. It has increased from 3,372.02 (Mar 24) to 4,862.64, marking an increase of 1,490.62.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.71. This value is within the healthy range. It has increased from 1.52 (Mar 24) to 2.71, marking an increase of 1.19.
• For EV / EBITDA (X), as of Mar 25, the value is 20.56. This value exceeds the healthy maximum of 15. It has increased from 10.77 (Mar 24) to 20.56, marking an increase of 9.79.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.63. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 2.63, marking an increase of 1.33.
• For Retention Ratios (%), as of Mar 25, the value is 85.02. This value exceeds the healthy maximum of 70. It has decreased from 89.70 (Mar 24) to 85.02, marking a decrease of 4.68.
• For Price / BV (X), as of Mar 25, the value is 2.65. This value is within the healthy range. It has increased from 1.71 (Mar 24) to 2.65, marking an increase of 0.94.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.63. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 2.63, marking an increase of 1.33.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.02, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness